BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 15652885)

  • 1. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
    Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
    Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression.
    Bjercke S; Fedorcsak P; Abyholm T; Storeng R; Ertzeid G; Oldereid N; Omland A; Tanbo T
    Hum Reprod; 2005 Sep; 20(9):2441-7. PubMed ID: 15919773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates.
    Lahoud R; Al-Jefout M; Tyler J; Ryan J; Driscoll G
    Hum Reprod; 2006 Oct; 21(10):2645-9. PubMed ID: 16785261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian response and pregnancy outcome related to midfollicular LH levels in down-regulated women undergoing assisted reproduction.
    Ferrari B; Barusi L; Lanna M; Coppola F
    J Reprod Med; 2004 Mar; 49(3):148-52. PubMed ID: 15098883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of concentration of circulating luteinizing hormone in late-follicle phase on the outcome of in vitro fertilization for normogonadotrophic women].
    Sun H; Hu Y; Wang B; Chen Q; Zhang N; Chen H; Wang J; Xu Z
    Zhonghua Nan Ke Xue; 2004 Dec; 10(12):912-5. PubMed ID: 15638021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression and flare regimens of gonadotropin-releasing hormone agonist. Use in women with different basal gonadotropin values in an in vitro fertilization program.
    Toth TL; Awwad JT; Veeck LL; Jones HW; Muasher SJ
    J Reprod Med; 1996 May; 41(5):321-6. PubMed ID: 8725756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization.
    Kovacs P; Kovats T; Kaali SG
    Fertil Steril; 2010 Feb; 93(2):475-9. PubMed ID: 19200991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating hormone.
    Foong SC; Abbott DH; Lesnick TG; Session DR; Walker DL; Dumesic DA
    Fertil Steril; 2005 May; 83(5):1377-83. PubMed ID: 15866572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
    Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
    Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
    Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
    Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH.
    Balasch J; Vidal E; Peñarrubia J; Casamitjana R; Carmona F; Creus M; Fábregues F; Vanrell JA
    Hum Reprod; 2001 Aug; 16(8):1636-43. PubMed ID: 11473955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients.
    Elgindy EA; El-Haieg DO; El-Sebaey A
    Fertil Steril; 2008 Jun; 89(6):1670-6. PubMed ID: 17658520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures.
    Ruvolo G; Bosco L; Pane A; Morici G; Cittadini E; Roccheri MC
    Fertil Steril; 2007 Mar; 87(3):542-6. PubMed ID: 17126339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.